American healthcare conglomerate with CVS Pharmacy, CVS Caremark, and Aetna
The White House has convened a meeting with AI leaders to review a proposed cybersecurity framework for advanced models, following OpenAI's recent agent hacks and calls for greater government access. Attendees include executives from Hugging Face, Anthropic, and others; Meta and Alphabet may participate. Markets show mixed responses as investors watch the policy discussion unfold.
Foundayo, the oral GLP-1 weight-loss pill by Eli Lilly, has been authorised by the MHRA for weight management and type 2 diabetes. It will be available privately; NHS adoption depends on NICE evaluation. Several UK outlets report on uptake, pricing, side effects and competing pills, including Wegovy and Wegovy HD.
CVS Health has raised its 2026 guidance, citing stronger profits from its insurance and retail pharmacy segments and a marked improvement in its Aetna unit. The company is expanding GLP-1 weight-loss access through MinuteClinic, while flagging higher medical costs and macro risks.
Major US medical societies have issued unified guidance this week for flu, COVID-19 and RSV vaccines after the CDC’s advisory process has been disrupted. Updated COVID shots have FDA approval and manufacturers are shipping doses, but legal and policy disputes over federal recommendations continue to leave states and insurers uncertain about timing and coverage.
The U.S. Department of Justice and Walmart have reached a settlement over claims that Walmart pharmacies violated the Controlled Substances Act by failing to report red flags tied to opioid prescriptions. Walmart has not admitted liability. The settlement resolves claims from 2013 onward, with earlier related actions already settled in 2022. Walmart shares edged higher after the announcement.
Rhode Island Gov. Dan McKee is facing Helena Foulkes in a rematch for the Democratic nomination. The Washington Bridge reconstruction has become a central issue, with voters weighing safety, cost, and timely completion as campaign ads highlight differing records.
Investors are turning to quality stocks as higher borrowing costs and a slower AI-driven rally reshape the market. Banks and strategists say quality can weather the downturn, with durable earnings, strong balance sheets, and cash flow guiding the next phase. Top analysts highlight hyperscalers and select AI-adopters as key exposures.